KRAS and non-small cell lung carcinoma: Therefore, the Sequenom MassARRAY platform performs at least as well in (OPA = 99.1%) assessing KRAS mutation status in clinically available NSCLC FFPE samples as the ARMS platform (Table 4), with enhanced analytical sensitivity (Table 3).